While Wegovy is specifically designed for weight management, Ozempic also aids individuals with type 2 diabetes
Here are the average weight loss results based on the dose and timeline: 1 mg: 7.2% in 24 weeks and 8.7% in 48 weeks 4 mg: 12.9% in 24 weeks and 16.3% in 48 weeks 8 mg: 17.3% in 24 weeks and 23.9% in 48 weeks 12 mg: 17.5% in 24 weeks and 24.2% in 48 weeks Placebo: 1.6% in 24 weeks and 2.1% in 48 weeks The retatrutide clinical trials are still ongoing, with a phase IV planned after the current phase III
Novo said last week that CagriSema was "well-tolerated" and that the most common adverse effects were gastrointestinal, but they were "mild to moderate and diminished over time." "Investors are looking for treatment options that are best in class and will secure Novo's place in the obesity drug market," Soren Lontoft, pharma equity analyst at Sydbank, told CNBC over the phone Tuesday
No blend pharmacokinetics The components differ markedly in size, clearance, receptor signaling, and effective concentration
doi: 10.1079/PNS2002213 62 CaniPDLecourtEDewulfEMSohetFMPachikianBDNaslainDet al
